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ABSTRACT
Objective: The aim of the present study was to examine the inhibiting effects of quercetin contained in Sonchus arvensis leaf extract on the activity of 
xanthine oxidase, an essential enzyme for uric acid synthesis.
Methods: Activity test was conducted in vitro by measuring the activity of xanthine oxidase using ultraviolet spectrophotometry and in silico by 
determining the interaction of quercetin and allopurinol (as comparator drug) with xanthine oxidase enzyme in terms of hydrogen bonds and binding 
free energy. Docking simulations were performed by AutoDock 4.2 package.
Results: The active fraction, using the solvent n-hexane, ethyl acetate, and water, tested the inhibitory activity of the xanthine oxidase enzyme in vitro 
obtained, respectively, inhibitory concentration 50% of 263.19, 16.20, and 141.80 µg/ml. Isolates with highest activity identified as quercetin. The 
xanthine oxidase enzyme inhibitory activity in silico by molecular docking showed that quercetin has free energy binding −7.71 kcal/mol, more 
negative than that of allopurinol −5.63 kcal/mol.
Conclusion: This shows the affinity of quercetin stronger than that of allopurinol so that it can be predicted that quercetin was more potential to 
inhibit xanthine oxidase enzyme activity. Thus, the extract of the S. arvensis leaves containing the active compound quercetin was a potential use as 
antihyperuricemia.
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INTRODUCTION
The trend of back to nature in using natural ingredients and herbs is 
increasing worldwide so that herbal medicine is an interesting treatment 
option to be developed. In Indonesia, Sonchus arvensis leaf has been 
traditionally used in as hyperuricemia remedy [1]. Hyperuricemia occurs 
due to excessive production of uric acid or low excretion of the acid or 
a combination of both [2]. Increased production of uric acid caused 
partly by the intake of foods that contain purine, uric acid metabolism 
disorder and breakdown of purines too quickly in the body also causes 
high levels of uric acid in the blood [3]. Decrease the excretion of uric 
acid is the main cause of hyperuricemia and can be caused by idiopathic 
primary, renal insufficiency, the interaction of drugs, and alcohol [3]. The 
combination of both mechanisms may occur in glucose-6-phosphatase 
deficiency and deficiency of fructose-1-phosphate aldolase [2]. The 
production of uric acid is catalyzed by xanthine oxidase in the liver [4]. 
Inhibition of xanthine oxidase can be one of the therapeutic avenues 
for the treatment of hyperuricemia. Xanthine oxidase is an essential 
enzyme for uric acid synthesis that converts hypoxanthine into xanthine 
and xanthine into uric acid, thus reducing uric acid production. Uric 
acid is the final product of purine metabolism in human body that 
exits the body through urinary excretion. This substance has very low 
solubility and tends to form crystals. Uric acid accumulated in the 
joints is commonly found in the form of monosodium uric crystals that 
induces inflammatory reactions [5,6]. Allopurinol is used clinically in the 
treatment of gout. Currently, allopurinol is one of the most widely used 
modern medicines to inhibit the synthesis of uric acid [2].
The results of previous studies of the structure-activity relationships 
and classification of flavonoids as an inhibitor of xanthine oxidase and 
superoxide scavengers were performed in vitro states that flavonoids 
are group of natural products that have various biological activities 
and pharmacological such as antibacterial, antiviral, antioxidant, 
antimutagenic effects and can inhibit some enzymes. Some flavonoids 
have been reported to inhibit the enzyme xanthine oxidase and have 
the ability to capture free radicals. Therefore, flavonoids can be used in 
the treatment of gout and ischemia in humans with lower levels of uric 
acid and free radicals in the body. One of them is the flavonoid quercetin, 
which is an inhibitor of the enzyme xanthine oxidase and has the ability 
to capture free radicals [7]. This is in line with the results of other studies 
stating that flavones and flavonols planar such as chrysin, luteolin, 
kaempferol, quercetin, myricetin, and isorhamnetin can inhibit xanthine 
oxidase enzyme strongly, while flavonoids non-planar, isoflavones, and 
anthocyanidins only slightly inhibit [8]. Quercetin is flavonol compounds 
that are widespread in plants [9]. In silico study was needed to analyze 
the xanthine oxidase enzyme inhibitory activity by predicting the affinity 
and interaction between quercetin and the xanthine oxidase enzyme.
Computational chemistry with in silico study described that in biological 
systems, the resulting pharmacological activity is not only dependent on 
the chemical structure or position of atoms that bind to receptors but 
also involves intermolecular force as a whole is important for proper 
interaction and complementarity between the two molecules. Among 
the various interactions between molecules, hydrogen bonds are very 
important. Hydrogen bonds work within a limited distance and direction, 
while the electrostatic interaction works in all directions and a greater 
distance [10]. Molecules with very different chemical structure can bind 
to the same site of the receptor. Many examples are known for competitive 
inhibition between the molecules of various structures. The shape 
and nature of the molecules should be complementary to the receptor 
sites [10]. The entire structure of drug molecules is not always necessary 
to bind to the receptor because not all the atoms of the inhibitor molecule 
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involved in the interaction with the receptor protein [10]. This article 
presents the evaluation of complementary in terms of in silico and in vitro 
pharmacological activity-related quercetin contained in S. arvensis.
METHODS
Plant materials
S. arvensis leaf was collected from the botanical garden of Manoko in 
Lembang, West Java, Indonesia. The plant materials were authenticated 
at Herbarium Bandungense, the School of Life Sciences and Technology, 
and Bandung Institute of Technology.
Plant extraction
This study used the cold maceration method for extraction, with 96% 
ethanol extracting solvents for the dried and ground plant materials. 
The macerate accumulated was concentrated using rotary evaporator 
under reduced pressure.
Xanthine oxidase inhibitory in vitro assay
Activity test for xanthine oxidase inhibition was conducted in vitro 
using ultraviolet spectrophotometry as described in previous 
studies [4,11-13] with the slight modification. Xanthine oxidase 
enzyme from bovine milk (Sigma-Aldrich, Tokyo, Japan) was prepared 
by dilution of the enzyme to a final concentration 2 Units/ml. 1 mM 
xanthine substrate solution was made by adding 5 drops of 1.0 M NaOH 
to increase the solubility of xanthine. Ethanolic extracts were dissolved 
in 1% dimethyl sulfoxide and made the test concentration at 50, 100, 
and 200 mg/ml. Allopurinol is used as comparator drug; total volume of 
the assay mixture was 3.2 ml consisting of 1 ml sample S. arvensis extract 
at various concentration, 1 ml of 0.15 M phosphate buffer (pH 7.8), and 
100 µl solution of the enzyme xanthine oxidase. After pre-incubation of 
the test solution at 37°C for 15 minutes, the reaction was initiated by 
addition of 100 µl of xanthine substrate solution and incubated at 37°C 
for 30 minutes. The reaction was stopped by adding 1 ml of 1N HCl. 
Spectrophotometer absorbance at 295 nm, suggesting the formation 
of uric acid. Percent of inhibition of xanthine oxidase activity of the 
test sample was determined by measuring the absorbance of uric acid 
from the mixture without test extracts (blank samples) compared with 
the absorbance of a mixture of test extracts. Inhibitory concentration 
50% (IC50) values were obtained by linear regression analysis of a plot, 
a series of different sample concentrations against percent inhibition.
Xanthine oxidase inhibitory in silico assay
Xanthine oxidase inhibition assay was conducted in silico as described 
in previous studies [14-16] with the slight modification. The ligand 
binding domain 3D structure of bovine xanthine oxidase in complex with 
quercetin obtained from the Protein Data Bank (www.pdb.org) with PDB 
code 3NVY as well as quercetin and allopurinol. Preparation of ligands 
and receptors, docking process, and analysis was performed using the 
AutoDock Tools v.4.2 program package (http://autodock.scripps.edu).
RESULTS AND DISCUSSION
Examination compound of S. arvensis leaf extract by thin-layer 
chromatography GF254 with the mobile phase chloroform:ethyl 
acetate:formic acid (6:4:0.2) and comparison to quercetin standard on 
Rf 0.6 indicates quercetin contained in the extract. Indeed, previous 
studies of the evaluation of flavonoids and antioxidant activity in 
S. arvensis showed that one of the components contained in S. arvensis 
is quercetin [17]. Table 1 shows the results of inhibitory activity of 
the xanthine oxidase enzyme in vitro and obtained quercetin with 
IC50 4.39 mg/mL, smaller than that of allopurinol 4.84 ug/ml. Indeed, 
previous studies on the structure-activity relationships and classification 
of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers 
were conducted in vitro and showed results that quercetin was a xanthine 
oxidase inhibitor with an additional superoxide scavenging activity [7].
Previous study showed that S. arvensis exhibits xanthine oxidase 
inhibitory activity and suggests that ethyl acetate extract of S. arvensis 
leaves has the most potent activity in inhibiting xanthine oxidase 
activity [12,13].  Sonchus arvensis L. leaves extract toxicity study showed 
there were no toxic effects after the use of single dose administration as 
acute toxicity test in mice, and also no toxic effects after repeated dose 
administration as subchronic oral toxicity studies in rats. Lethal dose 
of the extract was higher than 15 g/kg bw and classified as practically 
non-toxic. There were no abnormalities in behavior, hematological, 
clinical biochemistry, and urine parameters [18].
Molecular docking simulations in this study were conducted to analyze 
the xanthine oxidase enzyme inhibitory activity by predicting the affinity 
and interaction between quercetin and the xanthine oxidase enzyme and 
compared with allopurinol. It was done through energy predictions bond 
conformation and orientation of molecules in the active site to target 
receptors and modeling the interactions between the receptor and the 
ligand. The crystal structure of bovine xanthine oxidase in complex with 
quercetin used as the target receptors obtained from the PDB (www.
pdb.org) with PDB code 3NVY. Docking process using Genetic Algorithm 
Lamarckian facilities in AutoDock Tools v.4.2 program that ligands directed 
to various possible positions in the structure of target molecules [14]. 
Docking method validation was done by redocking natural ligand receptor 
on the active side. The validity of the docking method parameters evaluated 
based on the value root-mean-square deviation (RMSD) and declared valid 
if the value of RMSD smaller than 2.0 Å [19]. In this study, the RMSD was 
0.91 Å, indicating that methods and calculation parameter settings meet 
the criteria of validity docking methods. Fig. 1 shown the comparison of the 
natural ligand conformation, that is quercetin from X-ray crystal structure of 
the conformation obtained from the calculation with the docking parameter 
grid box coordinates x; y; and z were 39.512; 21.651; and 20.246.
Analysis was performed on free energy parameter binding; inhibition 
constants, hydrogen bonding, and interactions occurred between the 
ligand (quercetin and allopurinol) with amino acid residues at the active 
site receptors. The value of free energy can be used to predict the binding 
affinity and ability of a compound to inhibit the enzyme molecule [14]. 
Negative free energy of binding inhibition constants indicates good 
affinity between ligands and receptors. As shown in Table 2, quercetin 
in lowest conformation energy had free energy binding −7.71 kcal/mol, 
more negative than that of allopurinol −5.63 kcal/mol. This suggests 
the affinity of quercetin stronger than that of allopurinol so that it could 
be predicted that quercetin was more potential to inhibit xanthine 
oxidase enzyme. Indeed, previous research on finding study material 
that has potential as the enzyme xanthine oxidase inhibitor use in 
silico docking showed that flavonoids have interaction with the active 
site of the enzyme xanthine oxidase [15]. Previous studies report that 
Table 1: The results of the inhibitory activity of the xanthine 
oxidase enzyme in vitro of quercetin and allopurinol
Material 
tested
Percent of inhibition (%) IC50 (µg/ml)
50 µg/ml 100 µg/ml 200 µg/ml
Quercetin 58.72±2.81 75.67±2.05 95.18±1.82 4.39
Allopurinol 59.14±3.26 71.38±7.01 91.75±11.99 4.84
Fig. 1: The comparison between quercetin conformation of 
the natural ligand X-ray crystal structure (black) with the 
conformation obtained from docking calculations (gray)
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the molecular modeling flavonoids could inhibit the xanthine oxidase 
enzyme. The apigenin, quercetin, myrisetin, isoviteksin, genistein, and 
naringenin were competitive inhibitor, and the kinetic analysis showed 
that flavonoids bind to the active site of the enzyme [16]. Likewise, 
another study using molecular docking showed that flavonoids provide 
inhibitory activity on the xanthine oxidase enzyme so as to further 
development for the prevention and treatment of gout and related 
inflammatory conditions [15].
Inhibition constants were proportional to the free energy of binding, 
2.24 µM quercetin smaller than allopurinol 74.96 µM in the lowest 
conformation energy. It indicates quercetin easier to bind the xanthine 
oxidase enzyme than allopurinol. Quercetin showed intermolecular 
energy −9.50 kcal/mol lower than allopurinol with −5.63 kcal/mol, 
thus reinforcing predictions that the inhibitory activity of quercetin was 
greater than allopurinol.
Figs. 2 and 3 shows that quercetin had two hydrogen bonds at amino 
acid residue Glu802 and Thr1010 as well as allopurinol can form 
hydrogen bonds at amino acid residue Thr1010 and Glu802. Indeed, 
previous studies showed that the complement steric benefit from the 
structure of quercetin in the active site of the receptor by hydrogen 
bonds with residual catalytic at Arg880 and Glu802 as an inhibitor of 
flavonoids against xanthine oxidase which is useful for the treatment 
of hyperuricemia, gout, and diseases of inflammation [20]. In another 
study, it is also explained that the disposition of the substrate in the active 
site Arg880 and Glu802 was important for the conversion of xanthine to 
uric acid [21]. Results of other studies explain that the xanthine oxidase 
inhibitor had hydrogen bonds to Glu802, Arg880, and Glu1261 essential 
for enzyme reactions [22]. Thus, it appears that both quercetin and 
allopurinol could bind to the active side of the enzyme xanthine oxidase.
Most of the plant flavonoid binding to the sugar clusters that tend to 
be soluble in water is rarely found as aglycone. Flavonoid glycosides 
absorption in the body is very light, just flavonoid aglycones be able 
to pass through the intestinal wall. Hydrolysis occurs in the large 
intestine by intestinal microflora; hydrolytic enzymes of the intestinal 
microflora could convert certain flavonoid glycosides into the aglycone 
form then passively diffuses into the cell and provide a pharmacological 
activity [23]. Thus, the extract of the S. arvensis leaves containing the 
active compound quercetin was a potential use as antihyperuricemia.
CONCLUSION
S. arvensis under investigation containing quercetin as active compound 
exhibits xanthine oxidase inhibitory activity. The energy bonding 
of quercetin was more negative compared to that of allopurinol, 
suggesting more affinity of quercetin to the active site of the enzyme. 
Table 2: The results of in silico molecular docking of quercetin and allopurinol
Material tested Conformation Binding energy (kcal/mol) Inhibition constant (µM) Intermolecular energy (kcal/mol)
Quercetin 1 −7.71 2.24 −9.50
2 −7.70 2.29 −9.49
3 −7.70 2.28 −9.49
4 −7.69 2.31 −9.48
5 −7.69 2.29 −9.48
6 −7.69 2.32 −9.48
7 −7.68 2.33 −9.47
8 −7.68 2.36 −9.47
9 −7.68 2.34 −9.47
10 −7.57 2.81 −9.49
Allopurinol 1 −5.63 74.96 −5.63
2 −5.00 215.45 −5.00
3 −4.91 249.71 −4.91
4 −4.39 600.57 −4.39
5 −5.63 75.00 −5.63
6 −5.03 205.13 −5.03
7 −4.92 245.63 −4.92
8 −4.85 280.57 −4.85
9 −5.26 74.96 −5.26
10 −4.90 74.96 −4.90
Fig. 2: The interaction of quercetin ligand on the active side 
xanthine oxidase receptor
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Indeed, the in vitro result showing lower IC50 of quercetin than that of 
allopurinol. Thus, the S. arvensis leaf was potential to be developed as 
agent for treating hyperuricemia.
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